ScinoPharm Taiwan (神隆) announced on the 5th that it has successfully obtained US FDA approval for its Glatiramer Acetate (GA) Injection, indicated for the treatment of Multiple System Atrophy (MS). This marks ScinoPharm as the first pharmaceutical company in Taiwan to pass this high-difficulty regulatory review, signaling the nation's entry into high-barrier, globally competitive markets.
Read more
